Transperineal Parallel Biopsy of the Prostate: A New Approach of Tissue Sampling for Precision Medicine

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41:781–793. doi:10.1016/j.humpath.2010.02.011
   PubMed Web of Science ®Google Scholar
• Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685–689. doi:10.1038/ng.2279
   PubMed Web of Science ®Google Scholar
• Fraser M, Sabelnykova VY, Yamaguchi TN, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541:359–364. doi:10.1038/nature20788
   PubMed Web of Science ®Google Scholar
• Wedge DC, Gundem G, Mitchell T, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50:682–692. doi:10.1038/s41588-018-0086-z
   PubMed Web of Science ®Google Scholar
• Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–282. doi:10.1016/j.eururo.2020.09.046
   PubMed Web of Science ®Google Scholar
• Palermo G, Bassi P, Racioppi M, et al. Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression. Minerva urologica e nefrologica. 2020;72:214–222. doi:10.23736/S0393-2249.19.03377-0
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhao Y, Tian Y. Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies. Minerva urologica e nefrologica. 2019;71:373–380. doi:10.23736/S0393-2249.18.03093-X
   PubMed Web of Science ®Google Scholar
• Lovf M, Zhao S, Axcrona U, et al. Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. Eur Urol. 2019;75(3):498–505. doi:10.1016/j.eururo.2018.08.009
   PubMed Web of Science ®Google Scholar
• Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–892. doi:10.1016/j.eururo.2013.05.049
   PubMed Web of Science ®Google Scholar
• De Paoli-iseppi R, Johansson PA, Menzies AM, et al. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology. 2016;48:261–266. doi:10.1016/j.pathol.2016.01.001
   PubMed Web of Science ®Google Scholar
• Hognas G, Kivinummi K, Kallio HML, et al. Feasibility of prostate PAXgene fixation for molecular research and diagnostic surgical pathology: comparison of matched fresh frozen, FFPE, and PFPE tissues. Am J Surg Pathol. 2018;42:103–115. doi:10.1097/PAS.0000000000000961
   PubMed Web of Science ®Google Scholar
• Hubner N, Shariat S, Remzi M. Prostate biopsy: guidelines and evidence. Curr Opin Urol. 2018;28:354–359. doi:10.1097/MOU.0000000000000510
   PubMed Web of Science ®Google Scholar
• Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131. doi:10.1093/nar/gkw520
   PubMed Web of Science ®Google Scholar
• Roth A, Khattra J, Yap D, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11:396–398. doi:10.1038/nmeth.2883
   PubMed Web of Science ®Google Scholar
• Dang HX, White BS, Foltz SM, et al. ClonEvol: clonal ordering and visualization in cancer sequencing. Ann Oncol. 2017;28:3076–3082. doi:10.1093/annonc/mdx517
   PubMed Web of Science ®Google Scholar
• Lindberg J, Klevebring D, Liu W, et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol. 2013;63:347–353. doi:10.1016/j.eururo.2012.03.050
   PubMed Web of Science ®Google Scholar
• Boutros PC, Fraser M, Harding NJ, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015;47:736–745. doi:10.1038/ng.3315
   PubMed Web of Science ®Google Scholar
• Djavan B, Susani M, Bursa B, et al. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol. 1999;5:139–142. doi:10.1016/S0022-5347(01)62084-6
   PubMedGoogle Scholar
• Demirtas A, Sonmez G, Tombul ST, et al. Comparison of the upgrading rates of international society of urological pathology grades and tumor laterality in patients undergoing standard 12-core prostate biopsy versus fusion prostate biopsy for prostate cancer. Urol Int. 2019;103:256–261. doi:10.1159/000501528
   PubMed Web of Science ®Google Scholar
• Ruijter ET, van de Kaa CA, Schalken JA, et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996;180:295–299. doi:10.1002/(SICI)1096-9896(199611)180:3<295::AID-PATH663>3.0.CO;2-W
   PubMed Web of Science ®Google Scholar
• Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004;100:2362–2366. doi:10.1002/cncr.20243
   PubMed Web of Science ®Google Scholar
• Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85. doi:10.1038/ncpuro1296
   PubMedGoogle Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi:10.1056/NEJMoa1014618
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197. doi:10.1056/NEJMoa1207506
   PubMed Web of Science ®Google Scholar
• Toren PJ, Gleave ME. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl. 2013;15:342–349. doi:10.1038/aja.2013.38
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492–2503. doi:10.1200/JCO.2017.77.6880
   PubMed Web of Science ®Google Scholar
• Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes: figure 1. Cancer Discov. 2011;1:466–468. doi:10.1158/2159-8290.CD-11-0259
   PubMed Web of Science ®Google Scholar
• Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–495. doi:10.1158/2159-8290.CD-11-0130
   PubMed Web of Science ®Google Scholar
• Aparicio AM, Shen L, Tapia EL, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22:1520–1530. doi:10.1158/1078-0432.CCR-15-1259
   PubMed Web of Science ®Google Scholar
• Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20:890–903. doi:10.1158/1078-0432.CCR-13-1982
   PubMed Web of Science ®Google Scholar
• Tsai H, Morais CL, Alshalalfa M, et al. Cyclin D1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res. 2015;21:5619–5629. doi:10.1158/1078-0432.CCR-15-0744
   PubMed Web of Science ®Google Scholar
• Kronig M, Nanko N, Drendel V, et al. Single punch, double biopsy. SpringerPlus. 2016;5:1456. doi:10.1186/s40064-016-3141-1
   PubMedGoogle Scholar
• Sonmez G, Tombul ST, Demirtas T, et al. Risk factors associated with pain in fusion prostate biopsy. Prostate Int. 2020;8:185–189. doi:10.1016/j.prnil.2020.05.004
   PubMed Web of Science ®Google Scholar